On May 28, 2022, Dr. Tom Du, Chairman of Evergreen Therapeutics and Dr. Charles Lee, CMO of Evergreen Therapeutics, attended the "First Academic Forum of HwaGen medical thinks markets 2022" sponsored by HwaGen Pharma. The conference was strongly supported by the local government, industry associations, and research institutions.

At the meeting, a number of senior experts from pharmaceutical industry witnessed the launch ceremony of the one-stop CRO/CDMO platform of HwaGen Pharma, and discussed the future of small molecule innovative drugs. A roundtable discussion was held on the important role of small-molecule new drugs in the fight against COVID-19 and how to better attract financing for innovative drug companies under the current situation.

As leaders in innovative pharmaceuticals and as CRO enterprises in the domestic AI pharmaceutical field, Evergreen Therapeutics and HwaGen Pharma complement each other's strengths. With their high level of cooperation, they will jointly be building a new highland of innovative drugs in China. At the meeting, HwaGen Pharma officially appointed Dr. Tao Du as the company's Strategic Consultant and signed a strategic cooperation agreement with Evergreen Therapeutics.